Latest filings (excl ownership)
EFFECT
Notice of effectiveness
14 Mar 22
6-K
Biofrontera files Form 15F to suspend SEC Reporting Requirements and starts trading Level I ADS program on US OTC market
9 Mar 22
15F-12B
Securities registration termination (foreign)
9 Mar 22
POS AM
Prospectus update (post-effective amendment)
9 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Mar 22
25
Voluntary exchange delisting
24 Feb 22
6-K
Current report (foreign)
24 Feb 22
6-K
Current report (foreign)
22 Feb 22
6-K
Current report (foreign)
14 Feb 22
6-K
Current report (foreign)
1 Feb 22
6-K
Biofrontera announces preliminary revenue figures for the full year 2021
13 Jan 22
6-K
Current report (foreign)
29 Dec 21
6-K
Annual General Meeting
14 Dec 21
6-K
Current report (foreign)
13 Dec 21
6-K
Biofrontera AG obtains notice of allowance for US patent on PDT-lamp and treatment method
8 Dec 21
6-K
Biofrontera obtains notice of allowance for US patent on innovative illumination protocol
2 Dec 21
6-K
Biofrontera AG announces timing of the departure of the CEO
2 Dec 21
6-K
Current report (foreign)
2 Dec 21
6-K
Addition to the agenda of the Annual General Meeting on 14 December 2021 pursuant to section 122 (2) AktG at the request of a shareholder
30 Nov 21
6-K
Current report (foreign)
29 Nov 21
6-K
Current report (foreign)
29 Nov 21
6-K
Invitation to the Annual General Meeting
24 Nov 21
6-K
Biofrontera AG announces mediation results
19 Nov 21
6-K
Quarterly report Q3 2021
18 Nov 21
6-K
Biofrontera AG announces initiation of clinical studies
16 Nov 21
6-K
Current report (foreign)
10 Nov 21
6-K
Current report (foreign)
9 Nov 21
6-K
Current report (foreign)
3 Nov 21
6-K
Current report (foreign)
2 Nov 21
6-K
Current report (foreign)
2 Nov 21
6-K
Current report (foreign)
29 Oct 21
6-K
Current report (foreign)
28 Oct 21
6-K
Biofrontera AG receives FDA-approval of the BF-RhodoLEDĀ® XL lamp
22 Oct 21
6-K
Current report (foreign)
1 Oct 21
6-K
Biofrontera reports preliminary approximate revenues for the month of September 2021
1 Oct 21
6-K
Biofrontera reports preliminary revenue for the month of August 2021
8 Sep 21
6-K
Current report (foreign)
19 Aug 21
6-K
Pre-announcement of a financial report according to articles 114 - 117 WpHG
16 Aug 21
6-K
Current report (foreign)
12 Aug 21
6-K
Biofrontera reports preliminary revenue for the month of July 2021
9 Aug 21
Latest ownership filings
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
25 Feb 22
SC 13G
Biofrontera Inc.
10 Feb 22
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
21 Dec 21
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
29 Nov 21
3
Biofrontera Inc.
28 Oct 21
SC 13D/A
Maruho Co., Ltd.
25 Feb 21
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
27 Nov 20
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
23 Sep 20
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
28 Aug 20
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
12 Mar 20
SC 13D/A
Biofrontera AG
3 Feb 20
SC 13D/A
Biofrontera AG
29 Aug 19
SC 13D/A
Biofrontera AG
31 Jul 19
SC 13D
Biofrontera AG
24 Jul 19
SC 13D/A
Biofrontera AG
2 Jul 19
SC 13D/A
Biofrontera AG
25 Jun 19
SC 13D/A
Biofrontera AG
13 Jun 19
SC 13D/A
Biofrontera AG
7 Jun 19
SC 13D/A
Biofrontera AG
22 May 19
SC 13D/A
Biofrontera AG
12 Apr 19
SC 13G
Biofrontera AG
8 Feb 19
SC 13D/A
Biofrontera AG
20 Sep 18
SC 13D
Biofrontera AG
11 Jun 18